Talee Bio

Talee Bio is a biopharmaceutical company dedicated to developing gene therapies for cystic fibrosis. The company is developing two inhaled gene therapy candidates to treat all cystic fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a lentiviral gene therapy. Talee Bio was founded by world-class academic researchers from the University of Iowa, Children's Hospital of Philadelphia, and Militia Hill Ventures.